T Cell Lymphomas clinical trials

Explore recruiting t cell lymphomas clinical trials.

Recruiting t cell lymphomas studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

T Cell Lymphomas trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

BeCALM - Brentuximab vedotin in CutAneous T-cell Lymphomas (CTCL): post-allogeneic hematopoietic stem cell transplant Maintenance

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

CITY

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)

Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Relapsed/Refractory B Cell and T-Cell Lymphomas

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

T Cell Lymphomas trials by city

T Cell Lymphomas in Toronto T Cell Lymphomas in Vancouver T Cell Lymphomas in Montreal T Cell Lymphomas in Calgary T Cell Lymphomas in Edmonton T Cell Lymphomas in Ottawa T Cell Lymphomas in Winnipeg T Cell Lymphomas in Quebec City T Cell Lymphomas in Hamilton T Cell Lymphomas in Kitchener T Cell Lymphomas in London T Cell Lymphomas in Halifax T Cell Lymphomas in New York T Cell Lymphomas in Los Angeles T Cell Lymphomas in Chicago T Cell Lymphomas in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease